APRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aprea Therapeutics Inc (APRE) is not a strong buy for a beginner, long-term investor at this time. The stock lacks positive momentum, has weak financial performance, and no significant catalysts to drive growth in the near term. While insider buying is a positive signal, the company's declining revenue and net income, coupled with negative technical indicators, suggest a cautious approach.
The MACD is negative and expanding, indicating bearish momentum. The RSI is at 31.414, close to oversold levels but still neutral. Moving averages are converging, showing no clear trend. Key support levels are at $0.777 and $0.73, with resistance at $0.93 and $0.977. The stock has a 70% chance of declining slightly in the short term.
Insiders are buying, with a 147.37% increase in buying activity over the last month. Analysts remain optimistic about the clinical potential of APR-1051, which could be a long-term growth driver.
Revenue dropped by 99.48% YoY in Q3 2025, and net income declined by 21.44% YoY. EPS also fell by 26.56% YoY. Technical indicators suggest bearish momentum, and there are no recent news or significant catalysts to drive the stock upward in the short term.
In Q3 2025, revenue dropped significantly by 99.48% YoY to $1,848. Net income fell to -$2,972,410, a 21.44% decline YoY. EPS decreased by 26.56% YoY to -$0.47. Gross margin remained stable at 100%. Overall, the financial performance is weak and reflects significant challenges.
Analysts have lowered price targets consistently over the past months. Wedbush reduced the target from $11 to $7, and H.C. Wainwright cut it from $5 to $4. Despite the cuts, analysts maintain Buy or Outperform ratings, citing the clinical potential of APR-1051 as a positive factor. However, dilution and shifting focus in the pipeline are concerns.
